Curia, Inc. is a global contract research, development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries. The company provides end-to-end services spanning drug discovery, process development, GMP manufacturing, and analytical testing for small molecules, biologics, generic APIs, and sterile drug products. Founded in 1991, Curia has more than 3,500 professionals operating across 23 facilities in North America, Europe, and India.
The company's technical capabilities include drug discovery, process development, GMP manufacturing, analytical testing services, and specialized work in small molecules, biologics, generic APIs, and sterile drug products. Curia originally gained recognition for discovering and developing the active pharmaceutical ingredient (API) in the drug Allegra.
With over 30 years of experience in the pharmaceutical industry, the organization operates as a contract development and manufacturing partner to companies in the pharmaceutical and biotechnology sectors. Its global footprint and integrated service model are designed to support partners from early-stage research through commercial-scale manufacturing.
